Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 26, 2021

Primary Completion Date

October 28, 2021

Study Completion Date

October 28, 2021

Conditions

Cognitive ImpairmentSchizophrenia

Interventions

DRUG

RL-007

Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing

DRUG

RL-007 Matching Placebo

Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing

Trial Locations (1)

Collaborative Neuroscience Research, Long Beach